Validation of the Osteoporosis-Specific Morisky Medication Adherence Scale in long-term users of bisphosphonates
To examine the psychometric properties and validity of the 8-item Osteoporosis-Specific Morisky Medication Adherence Scale (OS-MMAS-8) in postmenopausal women prescribed bisphosphonates (BPs) for at least 15 months.
A random sample of women aged ≥55 years with osteoporosis prescribed daily or weekly BPs was identified. Pharmacy fill data were extracted to calculate the medication possession ratio (MPR). Eligible women were stratified by low (<0.50), medium (0.50–0.79), or high (≥0.80) MPR, with the a priori goal of recruiting 133 participants in each group. OS-MMAS-8 scores can range from 0 to 8 and were categorized as low (<6), medium (6 to <8), and high (8) adherence. Internal consistency reliability (Cronbach’s alpha), test–retest reliability [intraclass correlation coefficients (ICCs)] and convergent validity (correlating OS-MMAS-8 with MPR and other self-reported measures) were assessed.
A total of 400 women out of 449 respondents reported that they were still taking their BPs at the time of the survey and completed OS-MMAS-8. Overall, 38.5, 34.3, and 27.3 % of participants had low, medium, and high OS-MMAS-8 scores, respectively. The mean (SD) MPRs according to OS-MMAS-8 scores (<6, 6 to <8 and 8) were 56.9 (22.6), 69.0 (24.9), and 76.7 (26.4), respectively. The correlation between OS-MMAS-8 and MPR was 0.36; p < 0.0001. Cronbach’s alpha was 0.74, and the ICC was 0.83 (95 % CI 0.76–0.88).
OS-MMAS-8 has acceptable psychometric properties for assessing medication adherence in postmenopausal women prescribed therapy for osteoporosis. Additional studies are needed to investigate the psychometric properties of OS-MMAS-8 in other settings and populations.
KeywordsAdherence Bisphosphonates Postmenopausal osteoporosis Psychometric Reliability Validity Morisky scale
We acknowledge the exemplary contributions of the study staff at the Department of Research & Evaluation, Kaiser Permanente Southern California (Alexander Carruth, Kimberly Saylor, Rong Wei, and Sandra Zakai). We thank David Macarios of Amgen Inc. for his insights on the Needs–Concerns Differential analyses. This study was funded by a contractual agreement between Kaiser Permanente Southern California and Amgen Inc., Thousand Oaks, CA.
Conflict of interest
Drs. O’Malley, Viswanathan and Grauer are employees of Amgen Inc. and own stock in Amgen Inc. Drs. Muntner, Gold, Silverman, and Morisky have served as advisors for Amgen Inc. Drs. Muntner, Gold and Silverman have served as consultants for Amgen Inc. Drs. Reynolds and Muntner received research support from Amgen Inc. Dr. Silverman has served as an advisor for Lilly, Novartis and Pfizer/Wyeth. Dr. Silverman has served as a consultant for Genentech, Lilly, Novartis and Pfizer/Wyeth. Dr. Silverman has received research support from Lilly and Pfizer/Wyeth. This study was funded by a contractual agreement between Kaiser Permanente Southern California and Amgen Inc., Thousand Oaks, CA.
- 1.National Osteoporosis Foundation. (2013). What is osteoporosis? Retrieved June 19, 2013, from http://www.nof.org/articles/7.
- 3.Watts, N. B., Bilezikian, J. P., Camacho, P. M., Greenspan, S. L., Harris, S. T., Hodgson, S. F., et al. (2010). American association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis: Executive summary of recommendations. Endocrine Practice, 16(6), 1016–1019.PubMedCrossRefGoogle Scholar
- 5.Halpern, R., Becker, L., Iqbal, S. U., Kazis, L. E., Macarios, D., & Badamgarav, E. (2011). The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: A retrospective claims analysis of female health plan enrollees with osteoporosis. Journal of Managed Care Pharmacy, 17(1), 25–39.PubMedGoogle Scholar
- 12.Reynolds, K., Viswanathan, H. N., O’Malley, C. D., Muntner, P., Harrison, T. N., Cheetham, T. C., et al. (2012). Psychometric properties of the osteoporosis-specific Morisky Medication Adherence Scale in postmenopausal women with osteoporosis newly treated with bisphosphonates. The Annals of Pharmacotherapy, 46(5), 659–670.PubMedCrossRefGoogle Scholar
- 13.Koebnick, C., Langer-Gould, A. M., Gould, M. K., Chao, C. R., Iyer, R. L., Smith, N., et al. (2012). Sociodemographic characteristics of members of a large, integrated health care system: Comparison with US Census Bureau Data. The Permanente Journal, 16(3), 37–41.PubMedCentralPubMedCrossRefGoogle Scholar
- 19.Atkinson, M. J., Sinha, A., Hass, S. L., Colman, S. S., Kumar, R. N., Brod, M., et al. (2004). Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health and Quality of Life Outcomes, 2, 12.PubMedCentralPubMedCrossRefGoogle Scholar
- 23.Horne, R., Buick, D., Fisher, M., Leake, H., Cooper, V., & Weinman, J. (2004). Doubts about necessity and concerns about adverse effects: Identifying the types of beliefs that are associated with non-adherence to HAART. International Journal of STD and AIDS, 15(1), 38–44.PubMedCrossRefGoogle Scholar
- 26.Nunnaly, J. (1978). Psychometric theory. New York: McGraw-Hill.Google Scholar
- 30.Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.). New York: Lawrence Erlbaum.Google Scholar
- 33.Hatcher, L. (1994). A step-by-step approach to using the SAS system for factor analysis and structural equation modeling. Cary, NC: SAS Institute.Google Scholar
- 36.Breuil, V., Cortet, B., Cotte, F. E., Arnould, B., Dias-Barbosa, C., Gaudin, A. F., et al. (2012). Validation of the adherence evaluation of osteoporosis treatment (ADEOS) questionnaire for osteoporotic post-menopausal women. Osteoporosis International, 23(2), 445–455.PubMedCentralPubMedCrossRefGoogle Scholar